Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Results of Intracardiac Mesenchymal Stem Cell Transplantation in Patients With Cardiomyopathy.

Circulation journal : official journal of the Japanese Circulation Society·2019
Same author

Therapeutic potential of ghrelin in cardiac diseases.

Expert review of endocrinology & metabolism·2019
Same author

The effect of serum on the proliferation of bone marrow-derived mesenchymal stem cells from aged donors and donors with or without chronic heart failure.

Journal of tissue engineering and regenerative medicine·2016
Same author

Effects of ghrelin treatment on exertional dyspnea in COPD: an exploratory analysis.

The journal of physiological sciences : JPS·2015
Same author

Adipose-derived stem cell sheet transplantation therapy in a porcine model of chronic heart failure.

Translational research : the journal of laboratory and clinical medicine·2015
Same author

Decreased serum ghrelin levels in patients with acute myocardial infarction.

The Tohoku journal of experimental medicine·2013

Related Experiment Video

Updated: Jun 27, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

[Prostacyclin derivatives].

Noritoshi Nagaya1

  • 1Nagaya Cardiovascular and Respiratory Clinic

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 5, 2008
PubMed
Summary
This summary is machine-generated.

New prostacyclin derivatives, including beraprost sodium and ONO-1301, show promise for treating pulmonary arterial hypertension. These agents offer potential improvements over existing therapies for this serious lung condition.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Experiment Videos

Last Updated: Jun 27, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Pulmonary Medicine

Context:

  • Pulmonary arterial hypertension (PAH) is a severe condition with limited treatment options.
  • Current prostacyclin therapies require continuous intravenous administration due to short half-lives.
  • There is a need for more convenient and effective PAH treatments.

Purpose:

  • To review the development and efficacy of prostacyclin analogues for pulmonary arterial hypertension.
  • To introduce ONO-1301, a novel long-acting prostacyclin agonist with dual activity.
  • To evaluate the therapeutic potential of these agents in preclinical models.

Summary:

  • Epoprostenol (prostacyclin) improves survival in PAH but requires IV administration.
  • Beraprost sodium, an oral analogue, improves pulmonary hemodynamics in PAH patients.
  • ONO-1301, a long-acting prostacyclin agonist, attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats.

Impact:

  • Novel prostacyclin derivatives like beraprost sodium and ONO-1301 offer potential advancements in PAH treatment.
  • These agents may provide more convenient and effective therapeutic options for patients with pulmonary arterial hypertension.
  • Further research into these prostacyclin derivatives could lead to improved patient outcomes in PAH.